Follow
Rina M Mbofung
Rina M Mbofung
Fate Therapeutics
No verified email
Title
Cited by
Cited by
Year
Loss of PTEN promotes resistance to T cell–mediated immunotherapy
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ...
Cancer discovery 6 (2), 202-216, 2016
13432016
Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy
T Cascone, JA McKenzie, RM Mbofung, S Punt, Z Wang, C Xu, ...
Cell metabolism 27 (5), 977-987. e4, 2018
4482018
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice
C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ...
Clinical cancer research 19 (2), 393-403, 2013
3962013
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
RM Mbofung, JA McKenzie, S Malu, M Zhang, W Peng, C Liu, I Kuiatse, ...
Nature communications 8 (1), 451, 2017
1202017
The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression
L Huang, S Malu, JA McKenzie, MC Andrews, AH Talukder, T Tieu, ...
Clinical Cancer Research 24 (14), 3366-3376, 2018
852018
The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy
JA McKenzie, RM Mbofung, S Malu, M Zhang, E Ashkin, S Devi, ...
JNCI: Journal of the National Cancer Institute 110 (7), 777-786, 2018
732018
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
W Peng, LJ Williams, C Xu, B Melendez, JA McKenzie, Y Chen, ...
Clinical Cancer Research 25 (21), 6406-6416, 2019
392019
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators
J Hou, Y Wang, L Shi, Y Chen, C Xu, A Saeedi, K Pan, R Bohat, NA Egan, ...
Journal for immunotherapy of cancer 9 (2), 2021
242021
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity
S Punt, S Malu, JA McKenzie, SZ Manrique, EM Doorduijn, RM Mbofung, ...
Cancer Immunology, Immunotherapy 70, 1101-1113, 2021
212021
Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6 (2): 202–16
W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff
External Resources Crossref (DOI), 0
17
CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner
L Huang, Z Wang, C Liu, C Xu, RM Mbofung, JA McKenzie, H Khong, ...
Oncogene 36 (28), 4081-4086, 2017
112017
117 FT536 path to IND: ubiquitous targeting of solid tumors with an off-the-shelf, first-of-kind MICA/B-specific CAR-iNK cellular immunotherapy
J Goulding, B Hancock, R Blum, M Ge, S Gaidarova, P Rogers, ...
Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021
52021
Weiyi Peng
C Liu, L Williams, C Xu, RM Mbofung
Abstracts: AACR Virtual Special Conference: Endometrial Cancer: New Biology …, 2020
52020
Alloimmune defense receptor harnesses host immune cell activation to potentiate functional persistence and anti-tumor activity of off-the-shelf, cell-based cancer therapy
AM Williams, KL Hayama, Y Pan, B Groff, RM Mbofung, A Chang, C Chen, ...
Blood 140 (Supplement 1), 4547-4548, 2022
32022
Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
Q Hammer, K Perica, RM Mbofung, H van Ooijen, E Varady, M Jelcic, ...
Blood 140 (Supplement 1), 1165-1166, 2022
22022
A novel stealth strategy that activates adoptively transferred allogeneic immune cells and avoids rejection for off-the-shelf cell-based cancer therapy
AM Williams, K Hayama, Y Pan, B Groff, RM Mbofung, L Fong, ...
Blood 138, 4800, 2021
22021
Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer
P Hwu, JA Mckenzie, RM Mbofung, R Amaria
US Patent 10,894,044, 2021
22021
Off-the-shelf, iPSC-derived CAR-NK cells multiplexed-engineered for the avoidance of allogeneic host immune cell rejection
RM Mbofung, AM Williams, K Hayama, Y Pan, B Groff, T Dailey, S Reyes, ...
Blood 138, 2795, 2021
12021
OX40 agonist antibody-based combination therapy with PI3Kβ selective inhibitor enhances T cell immunity
W Peng, C Xu, B Melendez, H Jackson, JA McKenzi, LJ Williams, Y Chen, ...
Cancer Research 78 (13_Supplement), 4938-4938, 2018
12018
Abstract B105: HSP90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes
RM Mbofung, JA McKenzie, S Malu, C Liu, W Peng, I Kuiatse, L Williams, ...
Cancer Immunology Research 4 (11_Supplement), B105-B105, 2016
12016
The system can't perform the operation now. Try again later.
Articles 1–20